D MacGlashan1. 1. Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224, USA. dmacglas@jhmi.edu
Abstract
BACKGROUND: Clinical desensitization of patients to drugs involves progressive exposure to escalating doses of drug over a period of 24 h. In prior studies, this method was re-capitulated in vitro to also demonstrate loss of mast cell or basophil responsiveness. However, most signalling studies of human basophils have identified changes in signalling by using other methods of inducing cellular desensitization. OBJECTIVE: This study examined two well-described endpoints of basophil desensitization, loss of syk or FcεRI expression, under conditions of subthreshold desensitization. METHODS: The loss of FcεRI and syk was examined in human basophils. RESULTS: It was shown that both loss of syk and FcεRI/IgE occurred during an escalating series of stimulation (anti-IgE Ab) and that expression loss occurred despite the presence of little histamine release. If basophils were first cultured for 3 days in 10 ng/mL IL-3, the concentration-dependence of histamine release shifted to 100-fold lower concentrations of stimulus. However, loss of syk did not show any change in its EC50 while loss of FcεRI also shifted 100-fold. From the perspective of early signal element activation, the marked shift in the EC50 for histamine release was not accompanied by similar shifts in the EC50s for several signalling elements. The EC50s for phospho-Src, phospho-SHIP1, phospho-Syk, or phospho-Cbl did not change while the EC50s for phospho-Erk and the cytosolic calcium response did shift 100-fold. CONCLUSIONS: These studies show that under normal conditions, subthreshold desensitization leads to loss of two critical signalling molecules (FcεRI and syk) but under at least one condition, treatment with IL-3, it is possible to markedly blunt the loss of syk, but not FcεRI, while executing a proper subthreshold titration. These data also suggest that IL-3 modifies only the sensitivity of signalling elements that are downstream of syk activation.
BACKGROUND: Clinical desensitization of patients to drugs involves progressive exposure to escalating doses of drug over a period of 24 h. In prior studies, this method was re-capitulated in vitro to also demonstrate loss of mast cell or basophil responsiveness. However, most signalling studies of human basophils have identified changes in signalling by using other methods of inducing cellular desensitization. OBJECTIVE: This study examined two well-described endpoints of basophil desensitization, loss of syk or FcεRI expression, under conditions of subthreshold desensitization. METHODS: The loss of FcεRI and syk was examined in human basophils. RESULTS: It was shown that both loss of syk and FcεRI/IgE occurred during an escalating series of stimulation (anti-IgE Ab) and that expression loss occurred despite the presence of little histamine release. If basophils were first cultured for 3 days in 10 ng/mL IL-3, the concentration-dependence of histamine release shifted to 100-fold lower concentrations of stimulus. However, loss of syk did not show any change in its EC50 while loss of FcεRI also shifted 100-fold. From the perspective of early signal element activation, the marked shift in the EC50 for histamine release was not accompanied by similar shifts in the EC50s for several signalling elements. The EC50s for phospho-Src, phospho-SHIP1, phospho-Syk, or phospho-Cbl did not change while the EC50s for phospho-Erk and the cytosolic calcium response did shift 100-fold. CONCLUSIONS: These studies show that under normal conditions, subthreshold desensitization leads to loss of two critical signalling molecules (FcεRI and syk) but under at least one condition, treatment with IL-3, it is possible to markedly blunt the loss of syk, but not FcεRI, while executing a proper subthreshold titration. These data also suggest that IL-3 modifies only the sensitivity of signalling elements that are downstream of syk activation.
Authors: M Yamaguchi; K Hirai; K Ohta; K Suzuki; S Kitani; T Takaishi; K Ito; C Ra; Y Morita Journal: J Allergy Clin Immunol Date: 1996-06 Impact factor: 10.793
Authors: Hans Jürgen Hoffmann; Edward F Knol; Martha Ferrer; Lina Mayorga; Vito Sabato; Alexandra F Santos; Bernadette Eberlein; Anna Nopp; Donald MacGlashan Journal: Curr Allergy Asthma Rep Date: 2016-07 Impact factor: 4.806
Authors: Marat V Khodoun; Suzanne C Morris; Wen-Hai Shao; Crystal Potter; Elizabeth Angerman; Artem Kiselev; Alexander E Yarawsky; Andrew B Herr; Katja Klausz; Anna Otte; Matthias Peipp; Fred D Finkelman Journal: J Allergy Clin Immunol Date: 2020-12-14 Impact factor: 10.793
Authors: Avanika Mahajan; Lama A Youssef; Cédric Cleyrat; Rachel Grattan; Shayna R Lucero; Christopher P Mattison; M Frank Erasmus; Bruna Jacobson; Lydia Tapia; William S Hlavacek; Mark Schuyler; Bridget S Wilson Journal: J Immunol Date: 2016-12-30 Impact factor: 5.422
Authors: Marat V Khodoun; Suzanne C Morris; Elizabeth Angerman; Crystal Potter; Richard Schuman; Mark Wunderlich; Joseph J Maciag; Kathryn C Sullivan Locker; James C Mulloy; Andrew B Herr; Fred D Finkelman Journal: J Allergy Clin Immunol Date: 2019-12-11 Impact factor: 10.793